The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Open accessAbstract
The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B. We report here the biochemical characterization of the human RET tyrosine kinase domain and the structure determination of the non-phosphorylated and phosphorylated forms. Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status. In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity. Longer forms of RET containing the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain. Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity. We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clinically relevant 4-anilinoquinazoline ZD6474. These structures explain why certain multiple endocrine neoplasia 2-associated RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,804
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
The GDNF family: Signalling, biological functions and therapeutic value
Airaksinen, M. S., & Saarma, M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn812 · Cited by 1,828
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
Maximum-likelihood density modification
Terwilliger, T. C. (2000) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444900005072 · Cited by 1,634
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Jing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81311-2 · Cited by 1,174
Characterization of a multicomponent receptor for GDNF
Treanor, J. J. S., Goodman, L., de Sauvage, F., Stone, D. M., Poulsen, K. T., Beck, C. D., Gray, C., Armanini, M. P., Pollock, R. A., Hefti, F., et al. (1996) · Nature · doi:10.1038/382080a0 · Cited by 1,080
A chemical switch for inhibitor-sensitive alleles of any protein kinase
Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., et al. (2000) · Nature · doi:10.1038/35030148 · Cited by 1,031
Activation of a novel human transforming gene, ret, by DNA rearrangement
Takahashi, M., Ritz, J., & Cooper, G. M. (1985) · Cell · doi:10.1016/0092-8674(85)90115-1 · Cited by 854
GDNF signalling through the Ret receptor tyrosine kinase
Durbec, P., Marcos-Gutierrez, C. V., Kilkenny, C., Grigoriou, M., Wartiowaara, K., Suvanto, P., Smith, D., Ponder, B., Costantini, F., Saarma, M., et al. (1996) · Nature · doi:10.1038/381789a0 · Cited by 811
Functional receptor for GDNF encoded by the c-ret proto-oncogene
Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A.-S., Sieber, B.-A., Grigoriou, M., Kilkenny, C., Salazar-Grueso, E., Pachnis, V., Arumäe, U., et al. (1996) · Nature · doi:10.1038/381785a0 · Cited by 796
Self-citationNovel functions and signalling pathways for GDNF
Sariola, H., & Saarma, M. (2003) · Journal of Cell Science · doi:10.1242/jcs.00786 · Cited by 648
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H., & Hiai, H. (1988) · PubMed · Cited by 442
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
GDNF/Ret signaling and the development of the kidney
Costantini, F., & Shakya, R. (2006) · BioEssays · doi:10.1002/bies.20357 · Cited by 327
The RET proto-oncogene in human cancers
Jhiang, S. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203857 · Cited by 298
Paratcha, G., Ledda, F., Baars, L., Coulpier, M., Besset, V., Anders, J., Scott, R., & Ibáñez, C. F. (2001) · Neuron · doi:10.1016/s0896-6273(01)00188-x · Cited by 290
Self-citationSPOT Synthesis: Epitope Analysis with Arrays of Synthetic Peptides Prepared on Cellulose Membranes
Frank, R., & Overwln, H. (2003) · Epitope Mapping Protocols · doi:10.1385/0-89603-375-9:149 · Cited by 258
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
Self-citationBesset, V., Scott, R. P., & Ibáñez, C. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006908200 · Cited by 255
Self-citationMultiple Reaction Monitoring to Identify Sites of Protein Phosphorylation with High Sensitivity
Unwin, R. D., Griffiths, J. R., Leverentz, M. K., Grallert, A., Hagan, I. M., & Whetton, A. D. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500113-mcp200 · Cited by 208
McTigue, M. A., Wickersham, J. A., Pinko, C., Showalter, R. E., Parast, C. V., Tempczyk-Russell, A., Gehring, M. R., Mroczkowski, B., Kan, C.-C., Villafranca, J. E., et al. (1999) · Structure · doi:10.1016/s0969-2126(99)80042-2 · Cited by 203
Barker, S., Kassel, D. B., Weigl, D., Huang, X., Luther, M., & Knight, W. B. (1995) · Biochemistry · doi:10.1021/bi00045a027 · Cited by 190
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
Ryan, A. J., & Wedge, S. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602603 · Cited by 177
Minireview: RET: Normal and Abnormal Functions
Santoro, M., Melillo, R. M., Carlomagno, F., Vecchio, G., & Fusco, A. (2004) · Endocrinology · doi:10.1210/en.2004-0922 · Cited by 175
Self-citationAnders, J., Kjær, S., & Ibáñez, C. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104968200 · Cited by 163
Self-citationManley, P. W., Cowan-Jacob, S. W., & Mestan, J. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.040 · Cited by 160
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
Blencke, S., Zech, B., Engkvist, O., Greff, Z., Őrfi, L., Horváth, Z., Kéri, G., Ullrich, A., & Daub, H. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.029 · Cited by 152
Vidal, M., Wells, S. A., Ryan, A. J., & Cagan, R. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4561 · Cited by 139
Yuan, Z., Guan, Y. A., Wang, L., Wei, W., Kane, A. B., & Chin, Y. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9390-9400.2004 · Cited by 138
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.
Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A., Gazit, A., Levitzki, A., & Santoro, M. M. (2002) · PubMed · Cited by 135
Self-citationRET activation by germline MEN2A and MEN2B mutations.
Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng, C., & Alberti, L. (1995) · PubMed · Cited by 134
Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine Kinase
Coulpier, M., Anders, J., & Ibáñez, C. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107992200 · Cited by 128
Self-citationSchlessinger, J. (2003) · Science · doi:10.1126/science.1082024 · Cited by 121
Iwashita, T., Kato, M., Murakami, H., Asai, N., Ishiguro, Y., Ito, S., Iwata, Y., Kawai, K., Asai, M., Kurokawa, K., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202742 · Cited by 120
Waltenberger, J. L., Uecker, A., Krøll, J., Frank, H., Mayr, U., Bjorge, J. D., Fujita, D. J., Gazit, A., Hombach, V., Levitzki, A., et al. (1999) · Circulation Research · doi:10.1161/01.res.85.1.12 · Cited by 111
Iwashita, T., Asai, N., Murakami, H., Matsuyama, M., & Takahashi, M. (1996) · PubMed · Cited by 110
MEN2A-RET-induced cellular transformation by activation of STAT3
Schuringa, J. J., Wojtachnio, K., Hagens, W. I., Vellenga, E., Buys, C. H. C. M., Hofstra, R. M. W., & Kruijer, W. (2001) · Oncogene · doi:10.1038/sj.onc.1204715 · Cited by 109
Identification of RET Autophosphorylation Sites by Mass Spectrometry
Kawamoto, Y., Takeda, K., Okuno, Y., Yamakawa, Y., Ito, Y., Taguchi, R., Kato, M., Suzuki, H., Takahashi, M., & Nakashima, I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312600200 · Cited by 107
Protein tyrosine kinases: autoregulation and small-molecule inhibition
Hubbard, S. R. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00383-4 · Cited by 91
Wang, W., Marimuthu, A., Tsai, J. Y., Kumar, A., Krupka, H. I., Zhang, C., Powell, B., Suzuki, Y., Nguyen, H. T., Tabrizizad, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600048103 · Cited by 90
Parast, C. V., Mroczkowski, B., Pinko, C., et al. (1998) · Biochemistry · doi:10.1021/bi981291f · Cited by 75
Li, S., Covino, N., Stein, E. G., Till, J. H., & Hubbard, S. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302425200 · Cited by 73
Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation
Bongarzone, I., Viganò, E., Alberti, L., Borrello, M. G., Pasini, B., Greco, A., Mondellini, P., Smith, D. P., Ponder, B. A. J., Romeo, G., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201759 · Cited by 73
A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET Mutations
Iwashita, T., Murakami, H., Kurokawa, K., Kawai, K., Miyauchi, A., Futami, H., Qiao, S., Ichihara, M., & Takahashi, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2227 · Cited by 72
Lougheed, J. C., Chen, R., Mak, P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406703200 · Cited by 65
Craven, R. A., Hanrahan, S. J., Totty, N., Harnden, P., Stanley, A. J., Maher, E. R., Harris, A. L., Trimble, W. S., Selby, P. J., & Banks, R. E. (2006) · PROTEOMICS · doi:10.1002/pmic.200500811 · Cited by 64
Self-citationKjaer, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg227 · Cited by 59
Novel protein kinases and molecular mechanisms of autoinhibition
Cheetham, G. M. T. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.10.011 · Cited by 58
Geneste, O. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.11.1989 · Cited by 57
Tegge, W. J., & Frank, R. (2003) · Humana Press eBooks · doi:10.1385/0-89603-392-9:99 · Cited by 49
Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi, M., Asai, N., Iwashita, T., Murakami, H., & Ito, S. (1998) · PubMed · Cited by 30
Receptor Tyrosine Kinases as Targets for Anticancer Therapeutics
Carlomagno, F., & Santoro, M. M. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054367266 · Cited by 17
Self-citation
Cited by
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Self-citationMedullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Metadata
- Authors
- Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 44
- Pages
- 33577-33587
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2039233888
- Cited by
- 302
- References
- 66
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.